Celldex Therapeutics, Inc.

CLDX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $-36.5M
Depreciation & Amortization $2.6M
Depreciation
Amortization $949.0K
Stock-Based Compensation $3.1M
Net Cash from Operating Activities $-29.9M
Investing Activities
Capital Expenditures $528.0K
Business Acquisitions
Net Cash from Investing Activities
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities
Net Change in Cash
Free Cash Flow $-30.4M
← Newer Page 3 of 3 Older →